Skip to content

Orion invites analysts and media to Financial Statement Release conference on Wednesday 9 February 2011


Orion will publish its Financial Statement Release for 2010 on Wednesday, 9 February 2011 approximately at 12:00 Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group's homepage at promptly after the publishing.

News conference for analysts and media on Wednesday 9 February 2011 at 13:30 EET

A news conference for analysts and media will be held on Wednesday 9 February 2011 at 13:30 EET at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review.

Live webcast and conference call

The event can be followed live as a webcast accessible at Questions can be asked also through conference call lines after the result presentation.

The conference call ID is 884,964 and the phone numbers to participate the conference are:

when calling from the United States +1 334 323 6203

when calling from other countries +44 (0)20 7162 0125

News conference recordings

A recording of the event in English will be available later the same day via a link on the Orion website. A recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

Orion Corporation


Timo Lappalainen

President and CEO
Jari Karlson





Orion Corporation


Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.